Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Targeted Radionuclide Diagnosis and Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives"
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 31 October 2023 | Viewed by 3812
Special Issue Editor
2. Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Uniwersytecka 7, 24-406 Kielce, Poland
Interests: radiobiology; molecular biology; genetics; radiation-induced DNA damage and repair; cancer; biomarkers; radiopharmaceuticals for targeted cancer therapy
Special Issue Information
It is a pleasure to invite you to submit a manuscript to this Special Issue of Molecules, entitled Targeted Radionuclide Diagnosis and Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives.
Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for the development and application of precise diagnostic imaging agents and effective therapeutic strategies for prostate cancer patients. In recent years, tremendous progress has been made in managing prostate cancer patients, partially due to achievements in radioligand-driven imaging and therapy. This Special Issue welcomes original research articles, communications and review articles dealing with the design, synthesis, and evaluation of new potentially active radiopharmaceuticals for the radionuclide-targeted diagnosis and therapy of prostate cancer. Studies using pre- and clinical data on radiotheranostics and nanoparticle-based radiopharmaceutical applications in prostate cancer diagnosis and therapy, including their safety and efficacy, are also welcome.
Prof. Dr. Anna Lankoff
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prostate cancer
- PSMA-targeting ligands
- nanoparticle-based radiopharmaceuticals
- targeted radioimaging and radiotherapy
- nuclear medicine
- medical oncology